DNAM-1 Antibody (4j67): sc-70980

DNAM-1 Antibody (4j67) is a mouse monoclonal IgG1 antibody that detects DNAM-1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), and flow cytometry (FCM). DNAM-1, also known as DNAX accessory molecule-1, plays a crucial role in the immune response by facilitating the adhesion of T cells and natural killer (NK) cells to target cells during cytotoxicity. This transmembrane glycoprotein, consisting of 318 amino acids and featuring two immunoglobulin-like domains, is essential for the activation of cytotoxic T lymphocytes (CTLs) as DNAM-1 enhances their ability to recognize and eliminate infected or malignant cells. DNAM-1′s presence on T cells and NK cells underscores its importance in immune surveillance and response, making DNAM-1 a vital component in the orchestration of effective immune reactions. Anti-DNAM-1 antibody (4j67) enables researchers to gain insights into the mechanisms of immune activation and the interactions between immune cells and their targets, ultimately contributing to a better understanding of immune system dynamics and potential therapeutic strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DNAM-1 Antibody (4j67) References:

1. LFA-1-dependent lipid raft recruitment of DNAM-1 (CD226) in CD4+ T cell.  |  Shirakawa, J., et al. 2006. Int Immunol. 18: 951-7. PMID: 16636013
2. DNAM-1: an amplifier of immune responses as a therapeutic target in various disorders.  |  Elishmereni, M., et al. 2008. Curr Opin Investig Drugs. 9: 491-6. PMID: 18465659
3. DNAM-1 expression marks an alternative program of NK cell maturation.  |  Martinet, L., et al. 2015. Cell Rep. 11: 85-97. PMID: 25818301
4. Development and Characterization of Novel Monoclonal Antibodies Against Human DNAM-1.  |  Okumura, G., et al. 2017. Monoclon Antib Immunodiagn Immunother. 36: 135-139. PMID: 28498033
5. Characteristic of TIGIT and DNAM-1 Expression on Foxp3+ γδ T Cells in AML Patients.  |  Jin, Z., et al. 2020. Biomed Res Int. 2020: 4612952. PMID: 32802845
6. NKG2D engagement on human NK cells leads to DNAM-1 hypo-responsiveness through different converging mechanisms.  |  Milito, ND., et al. 2023. Eur J Immunol. 53: e2250198. PMID: 36440686
7. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.  |  Kaito, Y., et al. 2024. Haematologica. 109: 1107-1120. PMID: 37731380
8. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.  |  Tahara, S., et al. 2024. Int Immunol. 36: 317-325. PMID: 38289706
9. CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells.  |  Perrone, C., et al. 2024. Front Immunol. 15: 1332781. PMID: 38390333
10. Cataloging circulating CD3+CD56+ NKT-like cells through a series of stimulating (NKG2D and DNAM-1) and inhibitory (PD-1, TIGIT, and Tim-3) immune checkpoint receptors in women diagnosed with precancerous cervical lesions or invasive cervical carcinoma.  |  Solorzano-Ibarra, F., et al. 2024. Immunol Lett. 269: 106889. PMID: 38945372

The preferred DNAM-1 antibody is DNAM-1 Antibody (D-11): sc-376736.